Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 11/20 | 0.69 |
| ▸ | CACNA1B | Q00975 | 11/20 | 0.69 |
| ▸ | CACNB1 | Q02641 | 11/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393961 | 0.86 | CACNA2D1 (0.66) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2792371 | 0.84 | CACNA2D1 (0.60) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL3395039 | 0.81 | CACNA2D1 (0.70) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL3394375 | 0.81 | CACNA2D1 (0.70) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL3426955 | 0.80 | CACNA2D1 (0.66) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2790442 | 0.79 | CACNA2D1 (0.56) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL3394465 | 0.79 | HTT (0.60) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2792554 | 0.79 | CACNA2D1 (0.64) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL3397733 | 0.77 | CACNA2D1 (0.66) | CACNA2D1CACNA1BCACNB1CACNA1CHTT | |
| SCHEMBL2794855 | 0.77 | CACNA2D1 (0.54) | CACNA2D1CACNA1BCACNB1CACNA1CHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | claimed |
| EP-1784401-A4 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-07-15 | — | — | EP | claimed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | claimed |
| EP-1784401-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-05-16 | — | — | EP | claimed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | claimed |
| WO-2006024160-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-03-09 | — | — | WO | claimed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | CACNA2D1 26/4885CACNA1B 3/4885CACNB1 25/4885 |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | ORAI1, ATP2A1, CACNA1B | CACNA2D1 26/4885CACNA1B 3/4885CACNB1 25/4885 |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | CACNA2D1 26/4885CACNA1B 3/4885CACNB1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.